LBA30ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC) - Smith, M R; Parker, C C; Saad, F; Miller, K; Tombal, B; Ng, Q S (Ann Oncol, 2018)
[Internet]